Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CABA

CABA - Cabaletta Bio Inc Stock Price, Fair Value and News

$2.86-0.16 (-5.30%)
Market Closed

Price Targets

CABA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CABA Price Action

Last 7 days

22.2%

Last 30 days

25.4%

Last 90 days

15.8%

Trailing 12 Months

19.2%

CABA RSI Chart

CABA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CABA Valuation

Market Cap

275.3M

Price/Earnings (Trailing)

-1.74

Price/Free Cashflow

-2.29

CABA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

CABA Fundamentals

CABA Earnings

Earnings (TTM)

-158.5M

Earnings Growth (Yr)

-46.48%

Earnings Growth (Qtr)

0.58%

CABA Profitability

Return on Equity

-113.66%

Return on Assets

-83.54%

Free Cashflow Yield

-43.68%

CABA Investor Care

Shares Dilution (1Y)

96.95%

Diluted EPS (TTM)

-2.53

CABA Alerts

  • 7 major insider buys recently.

About Cabaletta Bio Inc

CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
 CEO
 WEBSITEcabalettabio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES77

Cabaletta Bio Inc Frequently Asked Questions

CABA is the stock ticker symbol of Cabaletta Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Cabaletta Bio Inc is 275.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CABA's fair value in chart for subscribers.

The fair value guage provides a quick view whether CABA is over valued or under valued. Whether Cabaletta Bio Inc is cheap or expensive depends on the assumptions which impact Cabaletta Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CABA.